articleJournal of Clinical OncologyJun 22, 2010Closed access

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

PPPeter PaschkaRFRichard F. SchlenkVIVerena I. GaidzikMHMarianne HabdankJKJan Krönke

Heidelberg University · University Hospital Heidelberg · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE: To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations in acute myeloid leukemia (AML). PATIENTS AND METHODS: We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian AML Study Group (AMLSG) treatment trials AML HD98A and APL HD95 for mutations in exon 4 of IDH1 and IDH2. Patients were also studied for NPM1, FLT3, MLL, and CEBPA mutations. The median follow-up for survival was 6.3 years. RESULTS: IDH mutations were found in 129 patients (16.0%) -IDH1 in 61 patients (7.6%), and IDH2 in 70 patients (8.7%). Two patients had both IDH1 and IDH2 mutations. All but one IDH1 mutation caused substitutions…

Citation impact

791
total citations
FWCI
36.90
Percentile
100%
References
51
Citations per year

Authors

14

Topics & keywords

Topics
Keywords
  • NPM1
  • IDH2
  • CEBPA
  • Myeloid leukemia
  • Medicine
  • IDH1
  • Isocitrate dehydrogenase
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.